Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Memantine
Drug ID BADD_D01378
Description Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366].
Indications and Usage Memantine is used to manage moderate to severe Alzheimer's dementia [FDA label]. A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106].
Marketing Status approved; investigational
ATC Code N06DX01
DrugBank ID DB01043
KEGG ID D08174
MeSH ID D008559
PubChem ID 4054
TTD Drug ID D01JEU
NDC Product Code 72603-118; 24196-184; 60687-184; 65162-173; 0615-8192; 55154-4151; 62135-895; 0904-6506; 53746-169; 55111-597; 0904-6505; 65015-892; 53746-173; 60687-173; 62135-896; 65162-169; 70518-3297; 0615-8319; 55154-7637; 72603-119; 55111-596
UNII W8O17SJF3T
Synonyms Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145
Chemical Information
Molecular Formula C12H21N
CAS Registry Number 19982-08-2
SMILES CC12CC3CC(C1)(CC(C3)(C2)N)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cognitive disorder19.21.02.001; 17.03.03.0030.000568%
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000181%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Congenital eye disorder06.08.03.011; 03.01.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000665%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Bacterial infection11.02.01.005--Not Available
Benign gastrointestinal neoplasm16.05.01.001; 07.20.01.001--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Electrocardiogram change13.14.05.014--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000266%Not Available
Foetal disorder18.03.02.001--Not Available
Embolism24.01.01.009--
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.0070.000121%Not Available
Optic neuropathy17.04.05.005; 06.02.08.0020.000121%Not Available
Cardiac valve disease02.07.02.001--Not Available
Venous thrombosis limb24.01.02.0090.000121%Not Available
Abnormal behaviour19.01.01.0010.000508%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.001330%
Corneal disorder06.08.01.0040.000302%Not Available
Feeling of body temperature change08.01.09.012--Not Available
The 16th Page    First    Pre   16 17 18    Next   Last    Total 18 Pages